ATHENEX INC (ATNX) Stock Price, Quote, News and Overview
NASDAQ:ATNX - Nasdaq - US04685N2027 - Common Stock - Currency: USD
ATNX Quote, Performance and Key Statistics
0.2031
-0.06 (-23.39%)
The current stock price of ATNX is 0.2031 USD. In the past month the price decreased by -82.49%. In the past year, price decreased by -97.95%.
ATNX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ATNX
Company Profile
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. The company is headquartered in Buffalo, New York and currently employs 269 full-time employees. The company went IPO on 2017-06-14. The firm is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The firm's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is focused on the sales and marketing of its specialty drugs and the market development of its drugs. Its clinical pipeline in the Oncology Innovation Platform is derived from its technologies: Cell Therapy, based on natural killer T (NKT) cells, and Orascovery, based on a P-glycoprotein pump inhibitor. Its product candidates include KUR-501, KUR-502, and KUR-503. KUR-501 is an autologous product in which NKT cells are engineered with a chimeric antigen receptor (CAR) targeting disialoganglioside (GD2). KUR-503 is an allogeneic product in which NKT cells are engineered with a CAR targeting glypican-3.
Company Info
ATHENEX INC
1001 Main St Ste 600
Buffalo NEW YORK 14203 US
CEO: Johnson Y.N. Lau
Employees: 269
Company Website: https://www.athenex.com/
Phone: 17168988625.0
ATHENEX INC / ATNX FAQ
What is the stock price of ATHENEX INC today?
The current stock price of ATNX is 0.2031 USD. The price decreased by -23.39% in the last trading session.
What is the ticker symbol for ATHENEX INC stock?
The exchange symbol of ATHENEX INC is ATNX and it is listed on the Nasdaq exchange.
On which exchange is ATNX stock listed?
ATNX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ATHENEX INC stock?
9 analysts have analysed ATNX and the average price target is 2.3 USD. This implies a price increase of 1029.99% is expected in the next year compared to the current price of 0.2031. Check the ATHENEX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ATHENEX INC worth?
ATHENEX INC (ATNX) has a market capitalization of 1.76M USD. This makes ATNX a Nano Cap stock.
How many employees does ATHENEX INC have?
ATHENEX INC (ATNX) currently has 269 employees.
Is ATHENEX INC (ATNX) expected to grow?
The Revenue of ATHENEX INC (ATNX) is expected to decline by -30.28% in the next year. Check the estimates tab for more information on the ATNX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ATHENEX INC (ATNX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ATNX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ATNX, evaluating the profitability, health, valuation and growth aspects
- ATHENEX INC (ATNX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ATHENEX INC (ATNX) Sales and EPS estimates to see what analysts future expectations are.
- ATHENEX INC (ATNX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ATHENEX INC (ATNX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ATHENEX INC (ATNX) Stock Chart to make your own analysis
- ATHENEX INC (ATNX) Latest news and press-releases to stay up to date.
Does ATHENEX INC (ATNX) stock pay dividends?
ATNX does not pay a dividend.
When does ATHENEX INC (ATNX) report earnings?
ATHENEX INC (ATNX) will report earnings on 2023-07-26, before the market open.
What is the Price/Earnings (PE) ratio of ATHENEX INC (ATNX)?
ATHENEX INC (ATNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-15.88).
ATNX Technical Analysis
ATNX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATNX. Both the profitability and financial health of ATNX have multiple concerns.
ATNX Financial Highlights
Over the last trailing twelve months ATNX reported a non-GAAP Earnings per Share(EPS) of -15.88. The EPS increased by 20.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ATNX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to ATNX. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 70.35% and a revenue growth -30.28% for ATNX